Industry
Biotechnology
Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes. The company was incorporated in 2012 and is headquartered in San Jose, California.
Loading...
Open
2.50
Mkt cap
142M
Volume
526K
High
2.56
P/E Ratio
-2.13
52-wk high
8.75
Low
2.42
Div yield
N/A
52-wk low
1.90
Portfolio Pulse from Benzinga Newsdesk
October 22, 2024 | 5:04 pm
Portfolio Pulse from Benzinga Newsdesk
October 18, 2024 | 10:52 am
Portfolio Pulse from Benzinga Newsdesk
October 17, 2024 | 12:05 pm
Portfolio Pulse from Henry Khederian
October 15, 2024 | 7:49 pm
Portfolio Pulse from Benzinga Insights
October 15, 2024 | 4:32 pm
Portfolio Pulse from Benzinga Newsdesk
October 15, 2024 | 4:16 pm
Portfolio Pulse from Benzinga Newsdesk
October 15, 2024 | 12:37 pm
Portfolio Pulse from Avi Kapoor
October 15, 2024 | 10:22 am
Portfolio Pulse from Benzinga Insights
October 14, 2024 | 4:30 pm
Portfolio Pulse from Benzinga Insights
October 14, 2024 | 12:09 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.